Toru Mukohara
Advertisement
Articles by Toru Mukohara
44 Results From the Phase 1/2 Study of Patritumab Deruxtecan (HER3-DXd), a HER3-Directed Antibody-Drug Conjugate (ADC), in Patients (pts) With HER3- Expressing Metastatic Breast Cancer (MBC)
ByIan E. Krop,Norikazu Masuda,Toru Mukohara,Shunji Takahashi,Takahiro Nakayama,Kenichi Inoue,Hiroji Iwata,Tatsuya Toyama,Yutaka Yamamoto,Damien Hansra,Masato Takahashi,Akihiko Osaki,Kumiko Koyama,Tatsuya Inoue,Takatoshi Yonekura,Joseph Mostillo,Shoichi Ohwada,Yoshimi Tanaka,David Sternberg,Kan Yonemori
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
A Look Back on the Top 10 Oncology Interviews in 2025
2
Spotlighting the Top 10 FDA Oncology Approvals in 2025
3
Zovegalisib Combo Confers Efficacy Benefit in PIK3CA-Mutated Breast Cancer
4
‘Relatively Low’ AEs Noted With Durvalumab/FLOT in Gastric/GEJ Cancer
5